Clinical Trial: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Locally Advanced Salivary Gland Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Brief Summary:
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent).Darolutamide is in a class of medications called androgen receptor inhibitors.It works by blocking the effects of androgen (a male reproductive…
Read more